NO331207B1 - Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav - Google Patents

Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav

Info

Publication number
NO331207B1
NO331207B1 NO20004502A NO20004502A NO331207B1 NO 331207 B1 NO331207 B1 NO 331207B1 NO 20004502 A NO20004502 A NO 20004502A NO 20004502 A NO20004502 A NO 20004502A NO 331207 B1 NO331207 B1 NO 331207B1
Authority
NO
Norway
Prior art keywords
eprosartan
preparation
pharmaceutical composition
composition
solvate
Prior art date
Application number
NO20004502A
Other languages
English (en)
Norwegian (no)
Other versions
NO20004502D0 (no
NO20004502L (no
Inventor
Gopadi M Venkatesh
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20004502D0 publication Critical patent/NO20004502D0/no
Publication of NO20004502L publication Critical patent/NO20004502L/no
Publication of NO331207B1 publication Critical patent/NO331207B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
NO20004502A 1998-03-11 2000-09-08 Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav NO331207B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7766098P 1998-03-11 1998-03-11
PCT/US1999/004651 WO1999045779A1 (en) 1998-03-11 1999-03-11 Novel compositions of eprosartan

Publications (3)

Publication Number Publication Date
NO20004502D0 NO20004502D0 (no) 2000-09-08
NO20004502L NO20004502L (no) 2000-11-07
NO331207B1 true NO331207B1 (no) 2011-10-31

Family

ID=22139347

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004502A NO331207B1 (no) 1998-03-11 2000-09-08 Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav

Country Status (21)

Country Link
EP (1) EP1061803B1 (pl)
JP (1) JP2002506010A (pl)
KR (1) KR20010041796A (pl)
CN (1) CN1299235A (pl)
AT (1) ATE508633T1 (pl)
AU (1) AU757547B2 (pl)
BR (1) BR9908691A (pl)
CA (1) CA2323363C (pl)
CY (1) CY1111738T1 (pl)
CZ (1) CZ303067B6 (pl)
DK (1) DK1061803T3 (pl)
ES (1) ES2366394T3 (pl)
HU (1) HU228574B1 (pl)
IL (1) IL138345A (pl)
NO (1) NO331207B1 (pl)
NZ (1) NZ506700A (pl)
PL (1) PL192545B1 (pl)
SI (1) SI1061803T1 (pl)
TR (1) TR200002646T2 (pl)
WO (1) WO1999045779A1 (pl)
ZA (1) ZA991922B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2213638C (en) 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
KR100634953B1 (ko) * 1998-07-20 2006-10-17 스미스클라인 비참 코포레이션 에프로사르탄을 포함하는 생물학적으로 강화된 경구 고형투여 형태의 제제
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
IL152081A0 (en) * 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
AU2004206109A1 (en) * 2003-01-21 2004-08-05 Ranbaxy Laboratories Limited Co-precipitated amorphous losartan and dosage forms comprising the same
MXPA05008142A (es) 2003-01-31 2005-09-30 Sankyo Co Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension.
MXPA06014448A (es) * 2004-06-23 2007-03-01 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema productor de endotelina endogena y antagonista del receptor at1.
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
EP2181109A4 (en) * 2007-07-25 2011-08-03 Hetero Drugs Ltd CRYSTALLINE PARTICLES OF EPROSARTAN MESYLATE AND PROCESS FOR PREPARING PURE EPROSARTAN
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS587609B2 (ja) 1979-06-17 1983-02-10 フロイント産業株式会社 粉体薬剤のコ−テング法
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU726694B2 (en) * 1996-03-29 2000-11-16 Smithkline Beecham Corporation Eprosartan dihydrate and a process for its production and formulation
BR9811926A (pt) * 1997-08-06 2000-08-22 Smithkline Beecham Corp Complexo de neutralização de carga de eprosartan arginila e um processo para a sua produção e formulação

Also Published As

Publication number Publication date
EP1061803A1 (en) 2000-12-27
CN1299235A (zh) 2001-06-13
AU2890999A (en) 1999-09-27
JP2002506010A (ja) 2002-02-26
CA2323363C (en) 2008-09-30
SI1061803T1 (sl) 2011-09-30
CZ303067B6 (cs) 2012-03-21
CY1111738T1 (el) 2015-10-07
CA2323363A1 (en) 1999-09-16
DK1061803T3 (da) 2011-08-29
PL343411A1 (en) 2001-08-13
KR20010041796A (ko) 2001-05-25
BR9908691A (pt) 2000-12-26
TR200002646T2 (tr) 2001-01-22
HUP0101243A1 (hu) 2002-05-29
NO20004502D0 (no) 2000-09-08
ES2366394T3 (es) 2011-10-19
WO1999045779A1 (en) 1999-09-16
PL192545B1 (pl) 2006-11-30
HU228574B1 (en) 2013-04-29
EP1061803B1 (en) 2011-05-11
ZA991922B (en) 1999-09-13
AU757547B2 (en) 2003-02-27
IL138345A (en) 2004-12-15
CZ20003288A3 (cs) 2001-03-14
ATE508633T1 (de) 2011-05-15
EP1061803A4 (en) 2007-12-26
NZ506700A (en) 2003-03-28
IL138345A0 (en) 2001-10-31
HUP0101243A3 (en) 2005-09-28
NO20004502L (no) 2000-11-07

Similar Documents

Publication Publication Date Title
NO331207B1 (no) Farmasoytisk sammensetning av eprosartan samt fremgangsmate for fremstilling og anvendelse derav
WO2000004862A3 (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
MY127793A (en) Novel form of s-omeprazole.
EP1504776A4 (en) ELEMENT FOR REGENERATING THE ARTICULATED ORANGE AND METHOD FOR THE PRODUCTION THEREOF, METHOD FOR REGENERATING ARTICLES OF ARTICLES AND ARTIFICIAL CARTILES FOR A TRANSPLANTATION
NO20003530D0 (no) Vedvarende frigivelsessammensetning, metode for dens produksjon og anvendelse derav
WO2002044156A3 (en) Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
DE60034728D1 (de) Verfahren zur Massenanfertigung von beschichteten, elektrochirurgischen Elektroden
RO118870B1 (ro) Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
TR199800608A3 (tr) Propanolamin türevleri, bunlarin üretim usulü.
DE69635998D1 (de) Nachweisverfahren für verbindungen, welche die somatostatin- und insulinproduktion stimulieren
NO20043371L (no) Kortikotropinfrigjorendefaktorreseptor-2 agonister
DE50012584D1 (de) Keramikhaltiges dispergat, verfahren zu dessen herstellung und verwendung des dispergates in dickschichtpasten
MY120085A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines.
WO2006052461A3 (en) Novel formulations of eprosartan with enhanced bioavailability
DE60129933D1 (de) Verfahren zum screening
ZA200005540B (en) New hydroxyindoles, their use as phosphodiestrase 4 inhibitors and method for producing same.
DK1411057T3 (da) [3,,4.a:3,4-c]carbazolderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
WO2000073333A3 (en) Ligand for cd7, and methods for use thereof
DE60226126D1 (de) Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
YU58702A (sh) Postupak za proizvodnju 5-arilnikotinaldehida
FR2842516B1 (fr) Composition d'ensimage pour verranne, procede utilisant cette composition et produits resultants
DE60130385D1 (de) Verfahren zur Erhöhung der Eierproduktion und Verfestigung von Eierschalen bei Geflügel
DE50010843D1 (de) Carboxamid-substituierte benzimidazol-derivate, verfahren zu ihrer herstellung und ihre verwendung als tryptase-inhibitoren
WO2000041472A3 (de) Bindungspartner für 5-ht5-rezeptoren zur migränebehandlung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees